We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SR Pharma Announces the Completion of Toxicology Studies for RNAi product candidate Atu027
News

SR Pharma Announces the Completion of Toxicology Studies for RNAi product candidate Atu027

SR Pharma Announces the Completion of Toxicology Studies for RNAi product candidate Atu027
News

SR Pharma Announces the Completion of Toxicology Studies for RNAi product candidate Atu027

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SR Pharma Announces the Completion of Toxicology Studies for RNAi product candidate Atu027"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SR Pharma plc has announced the completion of initial toxicology studies for its RNAi product candidate Atu027. These studies were conducted in Basel, Switzerland by RCC, an independent contract research organisation.

The results confirmed that there was no local problem at the site of infusion with this systemically administered product.

Atu027 is a reconstituted lyophilised material that was tested in repeated 4-hour and 24-hour continuous intravenous infusions. The drug candidate was given every third day over a period of 15 days.

As a consequence, advanced toxicology programs with this lead product candidate will start at the end of November 2006.

The GMP manufacturing process has already been established and scale-up to provide sufficient material for further pre-clinical and clinical testing is underway.

Iain Ross, Chairman of SR Pharma, said, "The results of these pilot toxicology studies are very encouraging and confirm that we are well on track with the pre-clinical programme for our systemically delivered RNAi product candidate, Atu027. Human clinical trials with Atu027 in oncology indications are now expected to commence in mid 2007."

Advertisement